Add BrightSurf on Google Email

Secret sugar pairings curb abnormal cell-growth signals

A team of scientists discovered that fleeting sugar pairings in cell membranes regulate epidermal growth factor receptor signaling, reducing unwanted cell division and potentially inhibiting cancer growth. This new mechanism reveals the importance of transient molecular interactions in maintaining membrane stability and regulating cell...

SourceOkinawa Institute of Science and Technology (OIST) Graduate University·JournalNature Communications·TypeExperimental study·DateAug 27, 2026

Some antibodies outmaneuver germs from sticking to cells

Researchers discovered that certain antibodies employ unusual tactics to block bacterial adhesion, including creating molecular wedges and conformational traps. These mechanisms could lead to the development of immune therapies targeting glycan-binding cell-attachment proteins produced by bacteria causing urinary tract infections.

SourceUniversity of Washington School of Medicine/UW Medicine·JournalNature Communications·TypeExperimental study·DateJan 7, 2026

How a small number of mutations can fuel outbreaks of western equine encephalitis virus

A single mutation in the spike protein of western equine encephalitis virus is enough to prevent it from attaching to human and horse cells. However, a change in the viral spike protein enables WEEV strains to attach to a different receptor, found on mammalian brain cells, which is shared by its cousin eastern equine encephalitis virus.

SourceHarvard Medical School·JournalCell·TypeExperimental study·DateApr 4, 2025

A diabetes, heart failure, and kidney disease medication is the first of its kind to significantly reduce both heart attacks and strokes

A new medication approved to treat type 2 diabetes and kidney disease also significantly reduces the risk of heart attacks and strokes among these patients. Sotagliflozin, a sodium-glucose cotransporter inhibitor, blocks proteins that help control blood sugar levels and has been shown to reduce cardiovascular events by 23%.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalThe Lancet·TypeRandomized controlled/clinical trial·DateFeb 14, 2025

Tiny antibodies to fight the dangerous effects of opioids

Researchers have discovered molecules capable of limiting the side effects of opioids by blocking the receptor responsible for their action. The scientists created even smaller molecules that retain the same properties, which could prove far more effective than current treatments in mitigating the harmful effects of opioids.

SourceUniversité de Genève·JournalNature Communications·TypeNews article·DateOct 9, 2024

Peptide synthesized at University of São Paulo acts as molecular shield to prevent SARS-CoV-2 from infecting cells

Researchers at the University of São Paulo developed a synthetic peptide that mimics the ACE2 receptor, blocking SARS-CoV-2 invasion and reducing inflammation in human lung cells and mice. The peptide could be customized for every variant, offering a fast-acting molecular shield against the virus.

Human odorant receptor for geosmin identified for the first time

Researchers have identified the human odorant receptor for geosmin, a compound responsible for the distinct 'earthy' to 'musty' odor found in soil, plants, and certain foods. The discovery could aid in developing novel detection systems to monitor food quality and water purity.

SourceLeibniz-Institut für Lebensmittel-Systembiologie an der TU München·JournalJournal of Agricultural and Food Chemistry·TypeExperimental study·DateAug 1, 2024

Mini lungs make major COVID-19 discoveries possible

Researchers have discovered that SARS-CoV-2 can infect more types of lung cells than previously thought, including those without known viral receptors. The study also found that the lung can independently muster an inflammatory antiviral response without immune system help when exposed to the virus.

SourceSanford Burnham Prebys·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateJul 23, 2024

Super-chilled brain cell molecules reveal how epilepsy drug works

Scientists at Johns Hopkins Medicine have discovered the mechanism of action of the widely-used epilepsy drug perampanel, which targets the AMPA receptor to dampen brain cell excitability. The study provides new insights into the potential applications of perampanel in treating other neurological conditions such as Alzheimer’s disease,...

SourceJohns Hopkins Medicine·JournalNature Structural & Molecular Biology·DateJun 10, 2024

Riesling wines: Human odorant receptor for characteristic petrol note identified for the first time

Researchers have identified the human odorant receptor responsible for the characteristic petrol note in German Riesling wines. The receptor, OR8H1, is triggered by UV exposure and high levels of carotenoids in grapes. This discovery may lead to new sensor technologies for food aromas and quality control purposes.

SourceLeibniz-Institut für Lebensmittel-Systembiologie an der TU München·JournalJournal of Agricultural and Food Chemistry·TypeExperimental study·DateApr 16, 2024

Novel therapeutic bispecific antibodies for B-cell lymphoma

Researchers developed novel therapeutic bispecific antibodies targeting IgM and B-cell surface antigens, which directly inhibited cell proliferation via cell-cycle arrest and apoptosis in vitro. These findings suggest that anti-IgM/B-cell surface antigen-binding specific antibodies are promising therapeutic agents for B-cell malignancies.

SourceImpact Journals LLC·JournalOncotarget·TypeExperimental study·DateApr 16, 2024

Mechanism of action of the hepatitis B and D virus cell entry inhibitor bulevirtide deciphered

Researchers deciphered the molecular structure of bulevirtide in complex with HBV/HDV receptor NTCP, revealing a unique 'plug' that inhibits virus entry. The study also sheds light on evolutionary adaptation of HBVs to host species and provides insights for developing smaller, more effective active agents.

SourceGerman Center for Infection Research·JournalNature Communications·TypeExperimental study·DateApr 10, 2024

Study suggests an ‘odor sensor’ may explain male and female differences in blood pressure

A Johns Hopkins Medicine research team found a cell surface protein that senses odors and chemicals may be responsible for the long-known difference in blood pressure between females and males. The study, published in Science Advances, used data from mice and humans to investigate the link between an odor sensor and blood pressure.

SourceJohns Hopkins Medicine·JournalScience Advances·DateMar 20, 2024

Genetic test identifies patients with triple negative breast cancer who are unlikely to respond to immunotherapies

A new genetic test has identified patients with triple negative early-stage breast cancer who are unlikely to respond to immunotherapy drugs. The test, called ImPrintTN, can predict a patient's likelihood of responding to these treatments and help avoid severe side effects.

SourceEuropean Organisation for Research and Treatment of Cancer·TypeRandomized controlled/clinical trial·DateMar 19, 2024

A sense of touch: ASICs are the receptor for a proton synaptic messenger between Merkel cells and an afferent nerve

A study by University of Alabama at Birmingham researchers discovered that protons are the primary signals transmitting tactile sensations from Merkel cells to nerves. Protons bind to ASIC receptors on nerve endings, triggering an influx of sodium ions that propagate action potentials up the nerve towards the brain.

SourceUniversity of Alabama at Birmingham·JournalNeuron·TypeExperimental study·DateFeb 14, 2024

Plant receptors that control immunity and development share a common origin

Researchers have discovered that plant immune receptors and growth-related proteins share a common evolutionary ancestry, allowing for the creation of hybrid receptors with enhanced functionality. This breakthrough could lead to the development of disease-resistant crops by isolating and engineering immune receptors from various plants.

SourceRIKEN·JournalNature Communications·TypeExperimental study·DateFeb 1, 2024

Three articles in the Journal of Pharmaceutical Analysis uncover previously unknown drug and disease mechanisms

Researchers have identified promising treatment candidates for morphine tolerance and cancer, as well as a biomarker for kidney injury. A monoclonal antibody targeting the mu-opioid receptor has been shown to alleviate morphine tolerance and physical dependence, while inducing excessive mitochondrial fission in tumor cells. Additionall...

SourceCactus Communications·JournalJournal of Pharmaceutical Analysis·TypeExperimental study·DateDec 14, 2023

Texas lab unlocks keys to alcohol withdrawal headache

A study by University of Texas Health Science Center at San Antonio researchers found that corticotropin-releasing factor (CRF) activates immune cells in the dura membrane under the skull, leading to pain signals. This discovery may lead to the development of a small-molecule drug therapy to inhibit CRF and MrgprB2 interaction.

SourceUniversity of Texas Health Science Center at San Antonio·JournalNeuron·TypeExperimental study·DateOct 30, 2023

Researchers identify ‘switch’ to activate cancer cell death

A research team from the University of California - Davis Health has identified a crucial epitope on the CD95 receptor that can trigger programmed cell death in cancer cells. This finding could lead to improved cancer treatments and potentially enhance CAR T-cell therapy for solid tumors like ovarian cancer.

SourceUniversity of California - Davis Health·JournalCell Death and Differentiation·TypeExperimental study·DateOct 23, 2023

Synthetic peptide could reduce vascular problems associated with COVID-ARDS

Researchers have developed a synthetic peptide that could help reduce vascular problems associated with acute respiratory distress syndrome in COVID-19. The peptide, called TIP, works by binding to a subunit of the epithelial sodium channel, which helps maintain barrier function and prevent damage from viral proteins.

SourceMedical College of Georgia at Augusta University·JournalFrontiers in Immunology·DateOct 3, 2023